Table 4 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer

<p>Patient characteristics of the ICI–TKI group.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Bunpei Isoda (22273897) (author)
Autres auteurs:	Masanobu Shiga (22273900) (author), Shuya Kandori (20806494) (author), Shota Takahashi (22273903) (author), Akifumi Omiya (22273906) (author), Tomoki Ishida (22273909) (author), Kotoe Matsuda (22273912) (author), Hiromichi Sakurai (22273915) (author), Bryan J. Mathis (20803922) (author), Ken Tanaka (22273918) (author), Manabu Komine (22273921) (author), Masahiro Iinuma (22273924) (author), Akira Joraku (22273927) (author), Hiromitsu Negoro (17411086) (author), Masakazu Tsutsumi (22273930) (author), Takamitsu Inoue (22273933) (author), Jun Miyazaki (22273936) (author), Hiroyuki Nishiyama (18287202) (author)
Publié:	2025
Sujets:	Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology Clinical Research and Trials Antibody Immunotherapy Cell Signaling Clinical-stage Research Genitourinary Cancers Renal cancer Immunotherapy Toxicities/irAEs Immune Cells And The Microenvironment Protein Tyrosine Kinases Tumor Microenvironment
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires